Movement Alert|SELLAS Life Sciences Group Inc. Falls 8.35% in Regular Trading, Trading at $11.29

Market Focus
07/25

On July 25, SELLAS Life Sciences Group Inc. fell 8.35% in regular trading, trading at $11.29/share, with Turnover of $53.60 million.

Within the Biotechnology sector where SELLAS Life Sciences Group Inc. belongs, among individual stocks, AbbVie up 0.58%, Amgen up 1.17%, Gilead Sciences down 0.86%, Vertex Pharmaceuticals up 0.92%, Argenx SE down 1.3%.

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for various cancer indications. Its lead product candidate is galinpepimut-S (GPS), currently in Phase 3 clinical trials for the treatment of acute myeloid leukemia.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10